Amalgamated Bank lifted its position in Clovis Oncology (NASDAQ:CLVS) by 23.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,283 shares of the biopharmaceutical company’s stock after acquiring an additional 1,406 shares during the quarter. Amalgamated Bank’s holdings in Clovis Oncology were worth $331,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of CLVS. Palo Alto Investors LP lifted its position in shares of Clovis Oncology by 16.2% in the 1st quarter. Palo Alto Investors LP now owns 3,955,660 shares of the biopharmaceutical company’s stock valued at $208,859,000 after acquiring an additional 552,879 shares in the last quarter. Summit Trail Advisors LLC increased its stake in Clovis Oncology by 4,092.7% in the 1st quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock valued at $249,000 after buying an additional 243,313 shares during the period. State of New Jersey Common Pension Fund D increased its stake in Clovis Oncology by 550.0% in the 1st quarter. State of New Jersey Common Pension Fund D now owns 260,000 shares of the biopharmaceutical company’s stock valued at $13,728,000 after buying an additional 220,000 shares during the period. Carmignac Gestion increased its stake in Clovis Oncology by 14.3% in the 1st quarter. Carmignac Gestion now owns 1,509,540 shares of the biopharmaceutical company’s stock valued at $79,704,000 after buying an additional 188,676 shares during the period. Finally, Amundi Pioneer Asset Management Inc. increased its stake in Clovis Oncology by 276.9% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 199,000 shares of the biopharmaceutical company’s stock valued at $10,507,000 after buying an additional 146,200 shares during the period. Institutional investors and hedge funds own 94.81% of the company’s stock.

Several research firms have weighed in on CLVS. ValuEngine upgraded shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 2nd. BidaskClub lowered shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a research note on Friday, June 8th. Zacks Investment Research lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Gabelli reiterated a “buy” rating on shares of Clovis Oncology in a research note on Monday, July 16th. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $73.00 price objective on shares of Clovis Oncology in a research note on Tuesday, June 12th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $79.65.

Clovis Oncology stock opened at $36.19 on Tuesday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -7.36 and a beta of 1.25. The company has a current ratio of 6.55, a quick ratio of 5.74 and a debt-to-equity ratio of 0.92. Clovis Oncology has a twelve month low of $35.32 and a twelve month high of $86.26.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.56). Clovis Oncology had a negative return on equity of 93.40% and a negative net margin of 382.83%. The business had revenue of $23.76 million for the quarter, compared to analyst estimates of $22.44 million. During the same quarter last year, the company earned ($1.29) EPS. The business’s revenue for the quarter was up 62.5% compared to the same quarter last year. equities research analysts forecast that Clovis Oncology will post -6.48 earnings per share for the current year.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: Penny Stocks, What You Need To Know

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.